Profile data is unavailable for this security.
About the company
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
- Revenue in HUF (TTM)805.16bn
- Net income in HUF158.85bn
- Incorporated1923
- Employees12.17k
- LocationRichter Gedeon Vegyeszeti Gyar NyrtGyomroi ut 19-21.BUDAPEST 1103HungaryHUN
- Phone+36 14314027
- Fax+36 12604891
- Websitehttps://www.gedeonrichter.com/hu-hu/
Mergers & acquisitions
Acquired company | RICHTER:BUD since announced | Transaction value |
---|---|---|
Richter-Helm Biologics GmbH & Co KG | -5.21% | 44.07m |
Richter-Helm Biotec GmbH & Co. KG | -5.21% | 77.94m |
Giskit MD BV | 3.41% | 33.59m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Camurus AB | 58.12bn | 14.61bn | 942.60bn | 213.00 | 64.47 | 18.00 | 62.51 | 16.22 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
Evotec SE | 323.41bn | -37.43bn | 991.97bn | 5.09k | -- | 2.20 | -- | 3.07 | -0.5371 | -0.5371 | 4.64 | 6.45 | 0.3634 | 19.15 | 5.44 | 165,751.60 | -4.21 | 2.35 | -5.08 | 2.83 | 26.78 | 25.86 | -11.57 | 6.22 | 2.09 | 0.0208 | 0.3404 | 0.00 | 21.59 | 23.29 | -181.51 | -- | 59.47 | -- |
MorphoSys AG | 93.89bn | -74.76bn | 1.01tn | 524.00 | -- | 51.94 | -- | 10.72 | -5.58 | -5.58 | 6.94 | 1.30 | 0.1077 | 1.18 | 3.86 | 454,729.60 | -8.58 | -10.25 | -9.78 | -11.61 | 78.62 | 85.92 | -79.63 | -78.53 | 2.84 | -- | 0.8403 | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Virbac SA | 491.31bn | 47.79bn | 1.20tn | 5.46k | 25.00 | 3.34 | 18.06 | 2.44 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
Dottikon ES Holding AG | 136.12bn | 34.68bn | 1.30tn | 694.00 | 37.11 | 3.79 | 30.22 | 9.58 | 6.24 | 6.24 | 24.49 | 61.10 | 0.3135 | 0.6339 | 5.39 | 498,861.30 | 7.99 | 7.48 | 9.58 | 8.48 | 67.58 | 78.94 | 25.48 | 22.35 | 1.65 | 101.25 | 0.1062 | -- | 26.80 | 15.09 | 47.94 | 27.70 | 30.78 | -- |
ALK-Abello A/S | 254.85bn | 25.67bn | 1.38tn | 2.82k | 61.51 | 6.40 | 33.55 | 5.40 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Siegfried Holding AG | 511.71bn | 45.10bn | 1.61tn | 3.93k | 33.64 | 4.48 | 20.56 | 3.14 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
Krka d.d. Novo Mesto | 711.76bn | 123.70bn | 1.62tn | 11.67k | 12.33 | 1.79 | 9.80 | 2.27 | 10.14 | 10.14 | 58.36 | 70.02 | 0.6627 | 1.35 | 3.96 | 154,829.10 | 11.51 | 12.64 | 13.75 | 15.12 | 56.84 | 57.29 | 17.37 | 18.71 | 2.54 | 19.10 | 0.0055 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
Richter Gedeon Vegyeszeti Gyar Nyrt | 805.16bn | 158.85bn | 1.67tn | 12.17k | 10.45 | 1.45 | 7.90 | 2.07 | 857.81 | 857.79 | 4,349.05 | 6,173.08 | 0.5931 | 1.71 | 4.08 | -- | 11.83 | 11.64 | 13.39 | 13.28 | 64.75 | 58.18 | 19.95 | 18.93 | 3.12 | 7.49 | 0.0159 | 39.70 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.38 |
Laboratorios Farmaceuticos ROVI SA | 326.84bn | 67.12bn | 1.71tn | 2.11k | 25.10 | 7.73 | 22.71 | 5.24 | 3.20 | 3.20 | 15.58 | 10.41 | 0.9883 | 1.04 | 5.13 | 392,946.00 | 20.29 | 18.90 | 28.88 | 25.58 | 59.35 | 59.82 | 20.53 | 20.13 | 0.8575 | -- | 0.1075 | 33.60 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
Hikma Pharmaceuticals Plc | 1.06tn | 70.06bn | 1.84tn | 8.97k | 26.27 | 2.26 | 11.05 | 1.73 | 0.6868 | 0.6868 | 10.39 | 7.99 | 0.6284 | 1.76 | 3.67 | 257,566.90 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
Orion Oyj | 468.81bn | 85.42bn | 1.85tn | 3.63k | 21.40 | 5.22 | 17.79 | 3.95 | 1.55 | 1.55 | 8.49 | 6.34 | 0.8088 | 1.57 | 5.56 | 327,588.10 | 14.72 | 19.47 | 18.03 | 24.16 | 55.30 | 59.38 | 18.20 | 20.71 | 1.75 | 94.79 | 0.1835 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
Zealand Pharma A/S | 18.11bn | -37.18bn | 2.02tn | 253.00 | -- | 22.39 | -- | 111.67 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Grifols SA | 2.60tn | 23.37bn | 2.08tn | 23.74k | 96.06 | 1.01 | 8.48 | 0.8012 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
DiaSorin SpA | 452.42bn | 62.98bn | 2.11tn | 3.23k | 33.44 | 3.32 | 18.16 | 4.67 | 2.87 | 2.87 | 21.49 | 28.83 | 0.3469 | 1.31 | 5.49 | 355,153.10 | 4.79 | 10.30 | 5.32 | 11.50 | 64.55 | 66.70 | 13.80 | 21.25 | 2.08 | 11.35 | 0.4368 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Aug 2022 | 9.46m | 5.08% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 5.83m | 3.13% |
Hermes Investment Management Ltd.as of 29 Feb 2024 | 4.79m | 2.57% |
Orbis Investment Management Ltd.as of 31 Dec 2023 | 4.44m | 2.39% |
Invesco Advisers, Inc.as of 29 Feb 2024 | 3.69m | 1.98% |
Seafarer Capital Partners LLCas of 31 Dec 2023 | 3.50m | 1.88% |
Schroder Investment Management Ltd.as of 29 Feb 2024 | 3.29m | 1.76% |
Norges Bank Investment Managementas of 31 Dec 2023 | 3.08m | 1.65% |
Templeton Asset Management Ltd.as of 29 Feb 2024 | 3.05m | 1.64% |
Fidelity Management & Research (Hong Kong) Ltd.as of 31 Jan 2024 | 2.27m | 1.22% |